STAT+: HHS presses ahead with effort to curb antidepressant use
Impact on your practice
This federal initiative positions therapists as key players in medication management conversations and creates potential new revenue streams through deprescribing support. However, therapists must be prepared with evidence-based knowledge and clear scope-of-practice boundaries to avoid liability.
Key facts
HHS officials met with mental health professionals to develop SSRI deprescribing guidance
Discussions included gaps in research on withdrawal effects and symptom recurrence
Guidance will recommend nonmedication alternatives including therapy
Signals major shift in federal clinical priorities and potential scope expansion for therapists
Therapy Companion analysis
This federal deprescribing initiative creates both opportunity and risk for your practice. On the opportunity side, HHS is explicitly positioning therapy as a first-line alternative to SSRIs, which means insurers and prescribers will increasingly refer patients to you for evidence-based alternatives before or during medication tapering. This could expand your referral base, particularly from primary care physicians managing patients with mild-to-moderate depression or anxiety. However, the financial upside depends on payer coverage: if deprescribing support becomes a billable service, you may see new CPT codes or authorization pathways emerge, but this is not guaranteed. More immediately, you face scope-of-practice risk. Therapists are not prescribers, yet you'll be expected to discuss medication withdrawal, recognize discontinuation syndromes, and coordinate with physicians on tapering timelines. Document your clinical recommendations carefully—never advise a patient to stop medication unilaterally, and always require physician sign-off. If a patient experiences withdrawal symptoms or relapse during deprescribing, liability exposure increases if your clinical notes don't show you flagged risks and maintained physician communication. Your reimbursement may also shift: if HHS guidance reduces SSRI prescribing, pharmaceutical companies lose revenue, but your therapy volume could increase if payers cover deprescribing-focused sessions at standard rates. The wild card is whether Medicaid and commercial plans will reimburse deprescribing coordination separately or fold it into existing session codes.
Background
This HHS initiative reflects a broader federal concern about overprescribing of antidepressants, particularly SSRIs, in primary care settings where patients often receive medication without concurrent therapy. The federal government is responding to research gaps around long-term SSRI efficacy, withdrawal effects, and symptom recurrence—areas where clinical evidence is incomplete. This is part of a larger mental health policy trend favoring stepped care models (therapy first, medication as adjunct) and deprescribing protocols similar to those already established for benzodiazepines and opioids. The timing matters: as payers face pressure to reduce unnecessary medication costs and improve outcomes, they're receptive to guidance that legitimizes therapy as an alternative, not just an add-on. For therapists, this represents a potential shift in how your work is valued relative to pharmacotherapy.
What you should do
Develop competency in evidence-based deprescribing protocols: Review current research on SSRI discontinuation syndromes, tapering schedules, and relapse rates. Familiarize yourself with symptom monitoring tools so you can distinguish withdrawal effects from recurrent depression during patient conversations with prescribers.
Clarify scope-of-practice language in your clinical documentation: Create a template note that documents your role as a therapy provider supporting medication management decisions made by the prescriber. Include explicit statements like 'Patient and I discussed deprescribing as an option; I recommended patient discuss with prescribing physician' to establish clear boundaries.
Establish formal communication protocols with prescribers in your referral network: Before HHS guidance becomes standard, proactively reach out to primary care physicians and psychiatrists you work with to discuss how you'll coordinate on deprescribing cases. Get agreements in writing about who monitors for withdrawal symptoms and how often you'll communicate.
Monitor payer policy updates and CPT coding changes: Watch for new authorization requirements, deprescribing-specific codes, or changes to session limits for patients in medication tapering. Contact your major payers (Medicaid, Blue Cross, Aetna, UnitedHealth) to ask whether deprescribing support will be covered separately or bundled into standard therapy rates.
Audit your current patient population for deprescribing candidates: Identify patients on long-term SSRIs with stable symptoms who might benefit from gradual tapering. Document clinical rationale and ensure physician involvement before initiating any deprescribing-focused treatment plan.
Notable excerpts
HHS officials met with mental health professionals to develop SSRI deprescribing guidance, with discussions including gaps in research on withdrawal effects and symptom recurrence.
Guidance will recommend nonmedication alternatives including therapy, signaling a major shift in federal clinical priorities.
Policy changes drive denial patterns
Therapy Companion tracks both: the policy shifts on this page and the denial patterns hitting your claims.
Related policy changes
[MA] H4895: Expanding access to mental health services
This bill aims to expand mental health service access in Massachusetts and has cleared committee with a favorable recommendation. Depending on final language, it could affect reimbursement rates, telehealth authorization, or insurance coverage requirements.
[TN] SB1248: AN ACT to amend Tennessee Code Annotated, Title 4; Title 8; Title 33; Title 39; Title 49; Title 53; Title 56; Title 63; Title 68 and Title 71, relative to mental health.
This comprehensive TN mental health bill touches multiple code sections and could affect licensure, scope of practice, insurance requirements, and workforce regulations. Therapists should monitor its progress closely as it moves through committee.
Advancing the Future of Behavioral Health Data Exchange
This policy direction addresses a critical pain point for therapists: the lack of integrated health data exchange with primary care and medical providers. Improved interoperability could reduce documentation burden, improve care coordination, and reduce liability from medication interactions or missed diagnoses. However, it may also increase compliance requirements and data security obligations.
Opinion: MAHA is rewriting the vocabulary of American mental health care
Federal deprescribing initiatives create new clinical and billing opportunities for therapists while potentially pressuring prescribing practices. Therapists should understand the evidence, reimbursement rules, and ethical considerations around medication tapering to protect clients and navigate changing clinical norms.